Molecular detection of xmrv infection
AssigneeAbbott Laboratories
InventorsNing Tang, Gregor W. Leckie
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. In particular, the invention relates to XMRV-related nucleic acids having significant diagnostic and screening utilities and methods of using the same.
Claims14
An isolated nucleic acid which is an oligonucleotide between about 15 and 50 nucleotides long comprising (i) any one of SEQ ID NOS:1-19 or (ii) a sequence that differs from any one of SEQ ID NOS:1-19 by no more than one or no more than two nucleotides, where said difference may be a deletion, insertion or substitution or (iii) a sequence which is at least 90 percent or at least 95 percent homologous to any one of SEQ ID NOS:1-19.
A pair of oligonucleotide primers for use in PCR to amplify a portion of a double stranded DNA copy of a XMRV genome where (a) a first primer is an oligonucleotide complementary to a first region on a first strand of the XMRV cDNA, said oligonucleotide being of a length of between about 15 and 50 nucleotides comprising (i) any one of SEQ ID NOS:1-19 or (ii) a sequence that differs from any one of SEQ ID NOS:1-19 by no more than one or no more than two nucleotides, where said difference may be a deletion, insertion or substitution or (iii) a sequence which is at least 90 percent or at least 95 percent homologous to any one of SEQ ID NOS:
- 1-19;
- and (b) a second primer which is an oligonucleotide complementary to second region of a second strand of the XMRV cDNA being of a length of between about 15 and 50 nucleotides, where the first region and the second region are between about 5 and about 200 nucleotides apart in the XMRV cDNA.
A method of determining that a cell contains XMRV, comprising detecting a cellular nucleic acid that specifically hybridizes to an oligonucleotide between about 15 and 50 nucleotides long comprising (i) any one of SEQ ID NOS:1-19 or (ii) a sequence that differs from any one of SEQ ID NOS:1-19 by no more than one or no more than two nucleotides, where said difference may be a deletion, insertion or substitution or (iii) a sequence which is at least 90 percent or at least 95 percent homologous to any one of SEQ ID NOS:1-19, wherein the presence of said cellular nucleic acid indicates that the cell is infected with XMRV.
A method of identifying an individual at risk for developing prostate cancer, comprising determining whether an XMRV is present in the individual by detecting, in a sample from the individual, a cellular nucleic acid that specifically hybridizes to an oligonucleotide between about 15 and 50 nucleotides long comprising (i) any one of SEQ ID NOS:1-19 or (ii) a sequence that differs from any one of SEQ ID NOS:1-19 by no more than one or no more than two nucleotides, where said difference may be a deletion, insertion or substitution or (iii) a sequence which is at least 90 percent or at least 95 percent homologous to any one of SEQ ID NOS:1-19, wherein the presence of said cellular nucleic acid indicates that XMRV is present in the individual and that the individual is at risk for developing prostate cancer.
Dependencies are inferred from the claim text.